Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion
Abstract To evaluate outcomes of intravitreal bevacizumab (IVB) treating macular edema (ME) after retinal vein occlusion (RVO) following pro re nata (PRN) regimen and investigate potential predictors of non-response. Retrospective analysis of 126 treatment-naive eyes with ME after RVO. Eyes were tre...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-27753-7 |
| _version_ | 1797952580296376320 |
|---|---|
| author | Wissam Aljundi Florian Gradinger Achim Langenbucher Haris Sideroudi Berthold Seitz Alaa Din Abdin |
| author_facet | Wissam Aljundi Florian Gradinger Achim Langenbucher Haris Sideroudi Berthold Seitz Alaa Din Abdin |
| author_sort | Wissam Aljundi |
| collection | DOAJ |
| description | Abstract To evaluate outcomes of intravitreal bevacizumab (IVB) treating macular edema (ME) after retinal vein occlusion (RVO) following pro re nata (PRN) regimen and investigate potential predictors of non-response. Retrospective analysis of 126 treatment-naive eyes with ME after RVO. Eyes were treated initially with IVB of 1.25 mg/ml. Therapy was switched in case of non-response. Outcome measures included best-corrected visual acuity (BCVA) and central macular thickness (CMT), which were recorded over 4 years of treatment. BCVA improved significantly during first 2 years. CMT decreased significantly during the 4-year follow-up period. Switching was required in 42 eyes (33%). 34 eyes (26.9%) were switched to steroids, while 8 eyes (6.3%) were switched to other anti-VEGF due to diagnosed glaucoma. Switching occurred after 12.4 ± 8.3 months and an average of 8 ± 4.1 IVBs. Compared with the treatment-responsive group, the treatment-unresponsive group had significantly worse BCVA, higher CMT and subfoveal choroidal thickness (SFCT) at baseline. Treatment IVB following PRN regimen showed significant functional and anatomic improvement in patients with ME after RVO. Switching was required in more than one third of eyes. Higher baseline SFCT could be considered as predictor for non-response to such therapy and thus an indicator of early switching. |
| first_indexed | 2024-04-10T22:49:48Z |
| format | Article |
| id | doaj.art-cc4e476db70941c2a008ee88e1ba6132 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-10T22:49:48Z |
| publishDate | 2023-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-cc4e476db70941c2a008ee88e1ba61322023-01-15T12:08:52ZengNature PortfolioScientific Reports2045-23222023-01-0113111010.1038/s41598-023-27753-7Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusionWissam Aljundi0Florian Gradinger1Achim Langenbucher2Haris Sideroudi3Berthold Seitz4Alaa Din Abdin5Department of Ophthalmology, Saarland University Medical Center UKSDepartment of Ophthalmology, Saarland University Medical Center UKSInstitute of Experimental Ophthalmology, Saarland UniversityDepartment of Ophthalmology, Saarland University Medical Center UKSDepartment of Ophthalmology, Saarland University Medical Center UKSDepartment of Ophthalmology, Saarland University Medical Center UKSAbstract To evaluate outcomes of intravitreal bevacizumab (IVB) treating macular edema (ME) after retinal vein occlusion (RVO) following pro re nata (PRN) regimen and investigate potential predictors of non-response. Retrospective analysis of 126 treatment-naive eyes with ME after RVO. Eyes were treated initially with IVB of 1.25 mg/ml. Therapy was switched in case of non-response. Outcome measures included best-corrected visual acuity (BCVA) and central macular thickness (CMT), which were recorded over 4 years of treatment. BCVA improved significantly during first 2 years. CMT decreased significantly during the 4-year follow-up period. Switching was required in 42 eyes (33%). 34 eyes (26.9%) were switched to steroids, while 8 eyes (6.3%) were switched to other anti-VEGF due to diagnosed glaucoma. Switching occurred after 12.4 ± 8.3 months and an average of 8 ± 4.1 IVBs. Compared with the treatment-responsive group, the treatment-unresponsive group had significantly worse BCVA, higher CMT and subfoveal choroidal thickness (SFCT) at baseline. Treatment IVB following PRN regimen showed significant functional and anatomic improvement in patients with ME after RVO. Switching was required in more than one third of eyes. Higher baseline SFCT could be considered as predictor for non-response to such therapy and thus an indicator of early switching.https://doi.org/10.1038/s41598-023-27753-7 |
| spellingShingle | Wissam Aljundi Florian Gradinger Achim Langenbucher Haris Sideroudi Berthold Seitz Alaa Din Abdin Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion Scientific Reports |
| title | Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion |
| title_full | Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion |
| title_fullStr | Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion |
| title_full_unstemmed | Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion |
| title_short | Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion |
| title_sort | choroidal thickness as a possible predictor of non response to intravitreal bevacizumab for macular edema after retinal vein occlusion |
| url | https://doi.org/10.1038/s41598-023-27753-7 |
| work_keys_str_mv | AT wissamaljundi choroidalthicknessasapossiblepredictorofnonresponsetointravitrealbevacizumabformacularedemaafterretinalveinocclusion AT floriangradinger choroidalthicknessasapossiblepredictorofnonresponsetointravitrealbevacizumabformacularedemaafterretinalveinocclusion AT achimlangenbucher choroidalthicknessasapossiblepredictorofnonresponsetointravitrealbevacizumabformacularedemaafterretinalveinocclusion AT harissideroudi choroidalthicknessasapossiblepredictorofnonresponsetointravitrealbevacizumabformacularedemaafterretinalveinocclusion AT bertholdseitz choroidalthicknessasapossiblepredictorofnonresponsetointravitrealbevacizumabformacularedemaafterretinalveinocclusion AT alaadinabdin choroidalthicknessasapossiblepredictorofnonresponsetointravitrealbevacizumabformacularedemaafterretinalveinocclusion |